Loading...
•
Mar 31, 2023
Bausch + Lomb Q1 2023 Earnings Report
Reported a strong first quarter with revenue growth across all segments.
Key Takeaways
Bausch + Lomb announced its first-quarter 2023 financial results, with revenues of $931 million, a 5% increase as reported and an 8% increase on a constant currency basis compared to the first quarter of 2022. The company's GAAP net loss attributable to Bausch + Lomb Corporation was $90 million, while adjusted EBITDA was $141 million.
Revenues of $931 million.
GAAP Net Loss Attributable to Bausch + Lomb Corporation of $90 Million.
Adjusted EBITDA (non-GAAP) of $141 Million.
Revenues Grew 5% as Reported and 8% on a Constant Currency Basis Compared to the First Quarter of 2022, Driven by Growth Across All Segments.
Bausch + Lomb
Bausch + Lomb
Bausch + Lomb Revenue by Segment
Revenue by Segment
Vision Care Revenue
CapyFin.comSurgical Revenue
CapyFin.comPharmaceuticals Revenue
CapyFin.com Forward Guidance
Bausch + Lomb provided guidance for the full year of 2023 with revenue range of $3.90 – $3.95 billion, reflecting anticipated growth of 5-6% on a constant currency basis and full-year Adjusted EBITDA range of $700 – $750 million.
Positive Outlook
- Full-year revenue range of $3.90 – $3.95 billion, reflecting anticipated growth of 5-6% on a constant currency basis
- Full-year Adjusted EBITDA range of $700 – $750 million
- $760 million at the mid-point of the full-year Adj. EBITDA guidance range, adjusted for currency headwinds
- Foreign exchange revenue and Adjusted EBITDA headwinds expected to be approximately $50 million and $35 million for the full year, respectively
Revenue & Expenses
Visualization of income flow from segment revenue to net income